Glycosaminoglycan-induced proinflammatory cytokine levels as disease marker in mucopolysaccharidosis

Recently, it has been shown disturbances in oxidant/antioxidant system and increases in some inflammatory markers in animal studies and in some Mucopolysaccharidoses (MPSs) patients. In this study, we aimed to determine the oxidative stress/antioxidant parameters and pro-inflammatory cytokine levels in the serum of MPS patients, in order to evaluate the possible role of inflammation in these patient groups regarding to accumulated metabolites. MPS I (n = 3), MPS II (n = 8), MPS III (n = 4), MPS IVA (n = 3), MPS VI (n = 3), and VII (n = 1) patients and 20 age-matched healthy subjects were included into the study. There was no statistically significant change in activities of SOD, Catalase, GSH-Px and lipid peroxidation levels in erythrocytes between the MPS patients and healthy controls. While IL-1alpha (p = 0.054), IL-6 (p = 0.008) levels, and chitotriosidase activity (p = 0.003) elevated in MPS3 patients, IL1 alpha (p = 0.006), IL-1 beta (p = 0.006), IL-6 (p = 0.006), IFN gamma (p = 0.006), and NFxB (p = 0.006) levels increased in MPS-6 patients. Elevated levels of IL-6, IL1 alpha and chitotriosidase activity demonstrated macrophage activation in MPSIII untreated with enzyme replacement. Our study showed for the first time that high levels of IL1 alpha, IL-6, IL1 beta and NFxB were present in MPSVI patients, demonstrating the induction of inflammation by dermatan sulphate. The low level of paraoxonase in MPSVI patients may be a good marker for cardiac involvement. Overall, this study provides important insights into the relationship between lysosomal storage of glycosaminoglycan and inflammation in MPS patients. It highlights possible pathways for the increased release of inflammatory molecules and suggests new targets for the development of treatments.

Automated summary

This study explores the oxidative stress, antioxidant parameters, and pro-inflammatory cytokine levels in MPS patients. The results suggest that inflammation plays a role in MPS patients, especially in untreated MPS III and MPS VI patients. The study also highlights potential targets for treatment development.